DCC-2618 is a potent inhibitor of wild type and mutant KIT, including refractory Exon 17 D816 KIT mutations.

The highly specific CSF1R inhibitor DCC-3014 exhibits Immunomodulatory and anti-invasive activities in cancer models. 

Translational research in a phase I proof-of-concept study supports that DCC-2618 is a pan-KIT inhibitor.

Pharmacokinetic (PK), Safety, and Tolerability Profile of DCC-2618 in a Phase 1 Clinical Trial Supports 150mg QD Selected for a Pivotal Phase 3 Study in Gastrointestinal Stromal Tumor (GIST). 

Inhibition of oncogenic and drug-resistant PDGFRA and KIT alterations by DCC-2618. 

Ripretinib (DCC-2618) Pharmacokinetics (PK) in a Phase 1 Study in Patients with Gastrointestinal Stromal Tumors (GIST) and other Advanced Malignancies: A Retrospective Evaluation of the PK Effects of Proton Pump Inhibitors (PPIs).